EUVIMEDEUVIMED entdecken
Crossref

Psoralidin acts as a dual protease inhibitor against PL pro and M pro of SARS ‐ CoV ‐2

Aditya Trivedi iD, Tushar Kushwaha, Ishani, Sudhanshu Vrati, Dharmender Gupta, Sarala Rani Kayampeta, Mohammad Khalid Parvez, Krishna Kishore Inampudi iD, Mohan Babu Appaiahgari iD, Deepak Sehgal iD

The FEBS Journal · 2025

DOI: 10.1111/febs.17380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Aditya Trivedi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institution of Eminence, Gautam Buddha Nagar, Uttar Pradesh, India. Hauptthemen laut MEDLINE: SARS-CoV-2, Protease Inhibitors, Coronavirus 3C Proteases, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, DST-SERB, Biotechnology Industry Research Assistance Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of new coronavirus variants and concerns about vaccine effectiveness against these novel variants emphasize the need for broad‐spectrum therapeutics targeting conserved coronaviral non‐structural proteins. Accordingly, a virtual library of 178 putative inhibitors targeting SARS‐CoV‐2 Papain‐like protease (PL pro ) was compiled through a systematic review of published literature and subsequently screened using molecular docking. Selected hits were analyzed for protease inhibitory activities, binding strength, and antiviral activities against HCoV229E‐based surrogate system and subsequently against SARS‐CoV‐2 for validation. Differences in potential modes of action were investigated using an HCoV229E‐based system, combined with in silico and biophysical methods against SARS‐CoV‐2 system. Of the 178 hits, 13 molecules showed superior docking scores against PL pro and met the inclusion criteria for further investigations. Of these, seven showed notable inhibitory activities against PL pro . Particularly, both Psoralidin and Corylifol‐A exhibited superior and, importantly, dual activities against SARS‐CoV‐2 M pro . Both molecules were found to be biologically active against HCoV229E and SARS‐CoV‐2; however, Psoralidin exhibited more consistent effects and was relatively well‐tolerated. Detailed in silico analyses of their interactions with the two proteases identified differences in their modes of action, primarily due to differences in their binding of PL pro . Based on these findings, we propose Psoralidin as a potential candidate for further development as a broad‐spectrum antiviral and Corylifol‐A as an ideal candidate for lead optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Protease InhibitorsCoronavirus 3C ProteasesAntiviral AgentsCoronavirus Papain-Like ProteasesBenzofuransMolecular Docking SimulationHumansCOVID-19 Drug TreatmentCOVID-19

Stichwörter der Autor:innen

HCoV‐229EPLproPsoralidinSARS‐CoV‐2in vitro

Substanzen

Protease InhibitorsCoronavirus 3C ProteasesAntiviral AgentsCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Benzofurans

Autor:innen und Institutionen

  • Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institution of Eminence, Gautam Buddha Nagar, Uttar Pradesh, India.
  • Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
  • Laboratory of Virology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, India.
  • Srikara Biologicals Pvt. Ltd., Tirupati, India.
  • Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Yenepoya (deemed to be) University, Mangalore, India.

ORCID-Profile: Aditya Trivedi, Krishna Kishore Inampudi, Mohan Babu Appaiahgari, Deepak Sehgal

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • DST-SERB
  • Biotechnology Industry Research Assistance Council
  • Science and Engineering Research Board
  • Indian Council of Medical Research
  • Researchers Supporting Project
  • School of Natural Sciences, Shiv Nadar Institute of Eminence, Gautam Buddha Nagar
  • M/s Srikara Biologicals Pvt. Ltd. (SBPL)

Zitieren

APA

Trivedi, A., Kushwaha, T., Ishani, Vrati, S., Gupta, D., Kayampeta, S. R., Parvez, M. K., Inampudi, K. K., Appaiahgari, M. B., & Sehgal, D. (2025). Psoralidin acts as a dual protease inhibitor against PL pro and M pro of SARS ‐ CoV ‐2. The FEBS Journal. https://doi.org/10.1111/febs.17380

Vancouver

Trivedi A, Kushwaha T, Ishani, Vrati S, Gupta D, Kayampeta SR, et al. Psoralidin acts as a dual protease inhibitor against PL pro and M pro of SARS ‐ CoV ‐2. The FEBS Journal. 2025. doi:10.1111/febs.17380

BibTeX
@article{Trivedi2025,
  author = {Trivedi, Aditya and Kushwaha, Tushar and Ishani and Vrati, Sudhanshu and Gupta, Dharmender and Kayampeta, Sarala Rani and Parvez, Mohammad Khalid and Inampudi, Krishna Kishore and Appaiahgari, Mohan Babu and Sehgal, Deepak},
  title = {Psoralidin acts as a dual protease inhibitor against PL pro and M pro of SARS ‐ CoV ‐2},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.17380}
}
Kostenlos starten →